Biotech & Pharma · Newsletter guide
The best biotech & pharma newsletters of 2026
: Hark’s ranked listBiotech and pharma professionals should start with BioPharma Dive Daily Dive, our best overall pick: a free weekday briefing on clinical trials, FDA actions, and deals. Endpoints News delivers wire-service speed on drug development, and The Readout adds STAT's weekday morning must-read. Hark's full ranking of 19 biotech & pharma newsletters is below, hand-verified for cadence, pricing, and publisher.
BioPharma Dive Daily Dive
Free weekday briefing built for people working inside biopharma.
Endpoints News
A dedicated newsroom with wire-service speed on deals and FDA decisions.
Fierce Pharma / Fierce Biotech
Comprehensive daily reporting on pharma marketing, manufacturing, and financing.
The Readout
STAT's biotech reporters round up clinical readouts, FDA decisions, deals, and market moves every weekday morning.
Hark’s top 10 biotech & pharma newsletters
Hand-ranked by the Hark News editorial team on breadth of coverage, original reporting, publisher authority, publishing frequency, and track record. Every one is free to read, or has a real free tier.
BioPharma Dive is Industry Dive's free weekday briefing on biotech and pharma: clinical trial readouts, FDA actions, and dealmaking, written for people inside the industry. Its advertising page claims 206,000 newsletter subscribers. The accessible end of the biopharma trade press.
Best for Biopharma professionals who want a free weekday briefing on clinical trial readouts, FDA actions, and dealmaking written for people inside the industry.
- Biopharma
- FDA
- Clinical Trials
- Daily Brief
Fierce Pharma and Fierce Biotech are the long-running flagship dailies of the drug-industry trade press, covering pharma marketing, manufacturing, clinical results, and biotech financing each weekday morning. High volume and comprehensive. The default inbox presence for industry professionals.
Best for Industry professionals who want comprehensive, high-volume daily coverage of pharma marketing, manufacturing, and biotech financing every weekday morning.
- Pharma
- Biotech Financing
- Manufacturing
- Trade Press
The Readout lands every weekday morning with a rundown of biotech news: clinical readouts, FDA decisions, deals, and market moves, linking to STAT's reporting. The signup page currently credits reporters Meghana Keshavan and Elaine Chen. The newsletter itself is free, though some linked stories sit behind the STAT+ paywall.
GEN Daily delivers headlines from GEN's newsroom, spanning bench research, tools and techniques, and biopharma business developments. It is free with a GEN account, which also unlocks the digital magazine; a separate paid GEN Edge tier carries premium analysis. GEN is the flagship publication of scientific publisher Mary Ann Liebert, Inc.
Endpoints News is a dedicated biopharma newsroom whose daily emails track drug development, FDA decisions, and dealmaking with wire-service speed and real sourcing. The core newsletters are free; deeper reporting sits behind an Endpoints subscription. A must-follow for anyone serious about the drug industry.
Best for Drug industry followers who want wire-service speed and real sourcing on drug development, FDA decisions, and dealmaking from a dedicated biopharma newsroom.
- Biopharma
- Drug Development
- FDA
- Dealmaking
GenePool is BioSpace's flagship daily digest, sent Monday to Friday with the day's biggest biopharma stories — clinical results, deals, regulatory news, and workforce trends. BioSpace pairs its newsroom with one of the industry's largest life-sciences job boards, so hiring and layoff coverage is a distinctive strand. Free; the form asks optional company/role questions.
PharmaVoice follows Industry Dive's signature model: a weekday email digest of original reporting on the people and trends shaping pharma, from C-suite moves to clinical and regulatory developments. Marketing materials say it is read by 54,000 industry decision-makers. Industry Dive relaunched the long-running PharmaVoice brand in this format in 2022.
In Brief is the daily email of pharmaceutical-technology.com, part of the GlobalData media network, compiling the site's coverage of pipelines, deals, manufacturing, and regulation informed by GlobalData's market-intelligence data. A companion digital magazine, Pharma Technology Focus, is offered on the same signup page. Free registration.
Good Day BIO was the trade association's hand-curated daily brief from Washington, DC, built to be scanned in about three minutes. BIO has since consolidated it into Bio.News, described on the signup page as the only weekly newsletter at the intersection of biotech, politics, and policy. Free signup at bio.org/bionews.
Fein, president of Drug Channels Institute, is a leading expert on U.S. pharmaceutical economics; posts typically appear a couple of times a week (often Tuesdays and Fridays) on PBMs, 340B, specialty pharmacy, Medicare Part D, and pricing policy. The site offers a free 'Subscribe to Drug Channels' email option and states a reach of more than 100,000 subscribers and followers.
More biotech & pharma newsletters
The rest of our ranked biotech & pharma newsletters, #11 through #19.
Labiotech.eu focuses on European biotech, and its weekly email has two sections: 'The Pick of the Week' summarizing the site's best article and 'The Roundup' of short news items on funding rounds, trials, and startups. The newsletter page states more than 16,000 pharma and biotech leaders subscribe. Free, unsubscribe anytime.
A monthly digest from the pharma market-intelligence firm Evaluate, collecting its most-read reports (such as World Preview), e-books, webinar recordings, and blog posts. It is a content-marketing roundup, not daily journalism. Subscription runs through a Thomson-style contact form (industry, country, marketing-consent checkbox) rather than a plain email box.
BioProcess Insider (BioProcess International)
Listen to BioProcess Insider (BioProcess International) freeA free weekly e-newsletter from the BioProcess International brand covering financial moves, capacity investments, regulation, and upstream/downstream processing developments in biomanufacturing. The peer-reviewed monthly BPI magazine is also free to qualified subscribers via magazine.bioprocessintl.com.
Fierce Pharma's newsletter lineup includes a manufacturing title (currently branded Fierce Manufacturing) alongside the flagship daily Fierce Pharma briefing on big pharma and FDA news. Coverage tracks facilities, recalls, FDA warning letters, and production deals. Signup is free via the Fierce Pharma newsletters page.
A free daily email described on the site as a '24 hour industry news round-up' of clinical trials coverage — trial starts and readouts, CRO news, and drug-development analysis drawn from GlobalData's intelligence. The 'In Brief' name appears in the site's newsletter signup forms; sister newsletters cover Pharmaceutical Technology and Medical Device Network.
Timmerman, a biotech journalist since 2001 (Seattle Times, Bloomberg News, Xconomy), founded the report in 2015. Subscribers get his weekly Frontpoints column on deals, financings, and data, plus in-depth reports and pieces from contributing writers such as David Shaywitz. Individual subscriptions run $199/year ($25/month, $65/quarter), with corporate licenses from $895 for five readers.
BioCentury pairs editorial publications (including the daily BioCentury Extra and weekly flagship analysis) with the BCIQ database, industry events, and a customizable Workspace portal. Its analysts and Ph.D.-staffed editorial team cover strategy, financing, regulation, and policy for biopharma decision-makers. Subscriptions are enterprise-priced and arranged through its account team — the site offers a trial request (and go.biocentury.com/SubscriptionForm2022.html) rather than self-serve email signup.
Subscribers get regulatory news and analysis from a team of 60+ journalists across seven countries — roughly 1,500 stories a year on FDA/EMA policy, biosimilars, generics, and market access. Access is a paid corporate subscription with email delivery; Citeline also offers a free quarterly 'Actionable Insights' newsletter and trial access.
Daily coverage of pharmaceutical business — M&A, licensing, clinical readouts, venture funding, and emerging companies — from Citeline's 60+ in-house journalists. Formerly Informa's Scrip World Pharmaceutical News; a paid subscription with trial access, delivered online and by email, plus the weekly 'Five Must-Know Things' podcast.
Hark’s Picks for Biotech & Pharma newsletters
The Hark editorial team researched each biotech & pharma newsletter to recommend the strongest pick for every kind of reader, from a quick daily overview to deeper reporting and analysis. These picks reflect Hark’s independent editorial judgment: publishers cannot pay for placement. Updated September 2026.
| Pick | Newsletter |
|---|---|
| Best overall | BioPharma Dive Daily Dive |
| Best for high-volume trade coverage | Fierce Pharma / Fierce Biotech |
| Best morning must-read | The Readout |
| Best for drug development and dealmaking | Endpoints News |
| Best for research and genomics | GEN Daily |
| Best for the day's top headlines | GenePool |
| Best for pharma executives | PharmaVoice |
| Best for biotech policy and Washington | Bio.News |
| Best for drug-pricing economics | Drug Channels |
| Best for European biotech | Labiotech.eu Newsletter |
| Best independent paid analysis | Timmerman Report |
| Best for regulatory intelligence | Pink Sheet |
| Best for biomanufacturing | BioProcess Insider (BioProcess International) |
| Best for clinical trials coverage | Clinical Trials Arena — In Brief |
Recommended bundles for biotech & pharma newsletters
Hark’s bundles make it easier to follow the news that matters to you without sorting through dozens of newsletters or hearing the same stories repeatedly. Each bundle brings together complementary biotech & pharma publications, selected by Hark’s editors to provide a useful mix of breaking news, original reporting, expert analysis and important perspectives. Whether you are looking to get ahead in your job or a curious student looking ahead for your career, our bundles are an efficient productivity hack to stay up to date and constantly learn.
Every morning, Hark takes the most important stories from all the newsletters in a bundle, removes the duplicates, and turns them into one short audio briefing: all the top stories in about five minutes. Tap a bundle and its newsletters come pre-selected when you start your free trial; add, drop, and compare until the mix fits.
Daily biopharma bundle
Professionals who want one fast, free morning read on the industry
BioPharma Dive Daily DiveEndpoints NewsThe Readout
Start with this bundleDeep trade coverage bundle
Readers who want comprehensive trade reporting across the whole industry
Fierce Pharma / Fierce BiotechGenePoolPharmaVoice
Start with this bundleComplete biopharma briefing
Insiders and investors who want to track the whole sector at once
Endpoints NewsFierce Pharma / Fierce BiotechThe Readout
Start with this bundleRegulatory and market intelligence
Teams that need paid, terminal-grade regulatory and competitive intelligence
Start with this bundleFrequently asked questions
What is the best biotech and pharma newsletter?
What is the best free biotech newsletter?
Are these biotech newsletters free?
What is the difference between Endpoints News and STAT's The Readout?
What is the best newsletter for FDA and clinical trial news?
Which biotech newsletter is best for investors?
What is the best daily biotech newsletter?
Is there a good newsletter on drug pricing and PBMs?
Which newsletter covers European biotech?
What do biopharma regulatory professionals read?
What is the most efficient way to keep up with biotech & pharma news?
How does Hark rank these biotech & pharma newsletters?
How often is this list updated?
Last updated: